GB Patent

GB2487183A — Cannabidivarin (CBDV) for use in the treatment of epilepsy

Assigned to GW Pharma Ltd · Expires 2012-07-18 · 14y expired

What this patent protects

The phytocannabinoid cannabidivarin (CBDV) in the treatment of epilepsy, in particular epilepsy characterised by generalised seizures or temporal lobe seizures where the CBDV may be used in an isolated form or as a botanical drug substance. Preferably, CBDV is used with one or mo…

USPTO Abstract

The phytocannabinoid cannabidivarin (CBDV) in the treatment of epilepsy, in particular epilepsy characterised by generalised seizures or temporal lobe seizures where the CBDV may be used in an isolated form or as a botanical drug substance. Preferably, CBDV is used with one or more therapeutically effective phytocannabinoids such as tetrahydrocannabivarin (THCV) and cannabidiol (CBD), and in combination with a standard anti-epileptic drug selected from ethosuximide, valproate or phenobarbital. A cannabis plant extract for use in the treatment of epilepsy, wherein the extract comprises at least 50 wt% of a phytocannabinoid fraction including CBDV as principal phytocannabinoid and CBD as secondary phytocannabinoid, and a non-phytocannabinoid fraction including monoterpenes and sesquiterpenes is also outlined.

Drugs covered by this patent

Patent Metadata

Patent number
GB2487183A
Jurisdiction
GB
Classification
—
Expires
2012-07-18
Drug substance claim
No
Drug product claim
No
Assignee
GW Pharma Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.